维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

7篇 您的检索式：作者名="Robert Mader"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast Cancer显示文摘	Susanne Taucher Margaretha Rudas Robert M. Mader Michael Gnant Emanuel Sporn Peter Dubsky Sebastian Roka Thomas Bachleitner Florian Fitzal Daniela Kandioler Catharina Wenzel Günther G. Steger Martina Mittlb?ck Raimund Jakesz	2003	Breast Cancer Research and Treatment2003，，3：	1
	2	Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer显示文摘	Susanne Taucher MD Margaretha Rudas Robert M. Mader Michael Gnant Peter Dubsky Sebastian Roka Thomas Bachleitner Daniela Kandioler Günther Steger Martina Mittlb?ck Raimund Jakesz	2004	Wiener Klinische Wochenschrift (-)2004，，1：	1
	3	Phmnacokinetics of 4 0 letrahv-dropyranyladriamyein given on a weekly schedule in patients with advanced breast cancer 显示文摘	Robert M Mader HZ Otto S	1995	Cancer Chemothrr phar- macol1995，37，：	1
	4	mi R ‐135b‐ and mi R ‐146b‐dependent silencing of calcium‐sensing receptor expression in colorectal tumors显示文摘	Irfete S. Fetahu Samawansha Tennakoon Kate E. Lines Charlotte Gr?schel Abhishek Aggarwal Ildiko Mesteri Sabina Baumgartner‐Parzer Robert M. Mader Rajesh V. Thakker Enik? Kállay	2016	Int. J. Cancer2016，，1：	1
	5	Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast Cancer显示文摘	Susanne Taucher Margaretha Rudas Robert M. Mader Michael Gnant Emanuel Sporn Peter Dubsky Sebastian Roka Thomas Bachleitner Florian Fitzal Daniela Kandioler Catharina Wenzel Günther G. Steger Martina Mittlb?ck Raimund Jakesz	2003	Breast Cancer Research and Treatment2003，，3：	1
	6	Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer显示文摘	Susanne Taucher MD Margaretha Rudas Robert M. Mader Michael Gnant Peter Dubsky Sebastian Roka Thomas Bachleitner Daniela Kandioler Günther Steger Martina Mittlb?ck Raimund Jakesz	2004	Wiener Klinische Wochenschrift (-)2004，，1：	1
	7	Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase Ⅱ trial EXACT显示文摘Objective: Advances in high-throughput genomic profiling and the development of new targeted therapies improve patient's survival. In gastrointestinal(GI) malignancies, the concept of personalized medicine(PM) was not investigated so far. The aim of this prospective study was to evaluate the efficacy of a personalized treatment in GI patients who failed standard treatment.Methods: Out of the original prospective clinical phase Ⅱ EXACT trial, 21(38%) GI cancer patients who had no further treatment options were identified. A molecular profile(MP) via a 50 gene next generation sequencing(NGS) panel in combination with immunohistochemistry(IHC) was conducted using real-time biopsy tumor material. Results were discussed by a multidisciplinary team(MDT) to translate the individual MP in an experimental treatment.Results: Of the 55 patients originally included in the EXACT trial, 21(38%) suffered from GI malignancies.The final analysis showed that 15(71%) patients had experienced a longer progression-free survival(PFS) upon experimental targeted treatment(124 d, quartiles 70/193 d), when compared with the PFS achieved by the previous conventional therapy(62 d, quartiles 55/83 d)(P=0.014). Thirteen(62%) patients receiving targeted treatment experienced a disease control according to Response Evaluation Criteria in Solid Tumors(RECIST). Median overall survival(OS) from the start of experimental therapy to time of censoring or death was 193 d(quartiles115/374 d).Conclusions: PM was not investigated in GI malignancies so far in a prospective trial. This study shows that treatment based on real-time molecular tumor profiling led to a superior clinical benefit, and survival as well as response was significantly improved when compared with previous standard medications.	Matthias Unseld Robert Mader Lukas Baumann Clarence Veraar Fritz Wrba Fredrik Waneck Markus Kieler Daniela Bianconi Walter Berger Maria Sibilia Leonhard Miillauer Christoph Zielinski Gerald W. Prager	2018	Chinese Journal of Cancer Research2018，30，5：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费